Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Marijuana use patterns among patients with inflammatory bowel disease.

Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J.

Inflamm Bowel Dis. 2013 Dec;19(13):2809-14. doi: 10.1097/01.MIB.0000435851.94391.37.

2.

Cannabis use amongst patients with inflammatory bowel disease.

Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H.

Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6. doi: 10.1097/MEG.0b013e328349bb4c.

PMID:
21795981
3.

Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease.

Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN.

Inflamm Bowel Dis. 2014 Mar;20(3):472-80. doi: 10.1097/01.MIB.0000440982.79036.d6.

PMID:
24407485
4.

Prevalence and Patterns of Marijuana Use in Young Adults With Inflammatory Bowel Disease.

Phatak UP, Rojas-Velasquez D, Porto A, Pashankar DS.

J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):261-264. doi: 10.1097/MPG.0000000000001474.

PMID:
27846066
5.

Patterns of cannabis use in patients with Inflammatory Bowel Disease: A population based analysis.

Weiss A, Friedenberg F.

Drug Alcohol Depend. 2015 Nov 1;156:84-9. doi: 10.1016/j.drugalcdep.2015.08.035. Epub 2015 Sep 14.

PMID:
26422462
6.

IBD: Patients with IBD find symptom relief in the Cannabis field.

Schicho R, Storr M.

Nat Rev Gastroenterol Hepatol. 2014 Mar;11(3):142-3. doi: 10.1038/nrgastro.2013.245. Epub 2013 Dec 24. No abstract available.

7.

Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.

Zelinkova Z, Bultman E, Vogelaar L, Bouziane C, Kuipers EJ, van der Woude CJ.

World J Gastroenterol. 2012 Dec 21;18(47):6967-73. doi: 10.3748/wjg.v18.i47.6967.

9.

A national survey on the patterns of treatment of inflammatory bowel disease in Canada.

Hilsden RJ, Verhoef MJ, Best A, Pocobelli G.

BMC Gastroenterol. 2003 Jun 5;3:10.

10.
11.

Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls.

Bessissow T, Van Keerberghen CA, Van Oudenhove L, Ferrante M, Vermeire S, Rutgeerts P, Van Assche G.

J Crohns Colitis. 2013 Dec;7(11):e580-7. doi: 10.1016/j.crohns.2013.04.011. Epub 2013 May 9.

PMID:
23664621
12.

Increased risk of pneumonia among patients with inflammatory bowel disease.

Long MD, Martin C, Sandler RS, Kappelman MD.

Am J Gastroenterol. 2013 Feb;108(2):240-8. doi: 10.1038/ajg.2012.406. Epub 2013 Jan 8.

13.

Cannabis use for chronic non-cancer pain: results of a prospective survey.

Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ.

Pain. 2003 Mar;102(1-2):211-6.

PMID:
12620613
14.

Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease.

Cury DB, Moss AC.

Inflamm Bowel Dis. 2010 Aug;16(8):1393-6. doi: 10.1002/ibd.21180.

PMID:
19998457
15.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
16.

The association between corticosteroid use and development of fractures among IBD patients in a population-based database.

Bernstein CN, Blanchard JF, Metge C, Yogendran M.

Am J Gastroenterol. 2003 Aug;98(8):1797-801.

PMID:
12907335
17.

Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.

Metge CJ, Blanchard JF, Peterson S, Bernstein CN.

Am J Gastroenterol. 2001 Dec;96(12):3348-55.

PMID:
11774948
18.

Prognosis after first-time myocardial infarction in patients with inflammatory bowel disease according to disease activity: nationwide cohort study.

Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Lamberts M, Khalid U, Nielsen OH, Torp-Pedersen C, Gislason GH, Hansen PR.

Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):857-62. doi: 10.1161/CIRCOUTCOMES.114.000918. Epub 2014 Oct 14.

19.
20.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228

Supplemental Content

Support Center